In interim analysis of phase 2 ASC2ESCALATE trial, patients with chronic-phase chronic myeloid leukemia who fail to respond ...

David Andorsky, MD, discusses efficacy and safety findings from the ASC2ESCALATE study of asciminib in chronic myeloid leukemia.

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for ...

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia N C P Cross and others Leukaemia, October 2023. Volume 37, Pages 2150 – 2167. European ...

On Monday, Tempus AI Inc. (NASDAQ:TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to immune ...

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to com ...

CHICAGO, June 02, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response ...

According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) ...

Chronic myeloid leukemia (CML) serves as a model for targeted cancer therapy, particularly through the development of tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 fusion gene, a molecular ...

In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%. 1 xM for TRM is designed to quantify ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...